SABCS 2017: Duration of Zoledronate Treatment After Adjuvant Chemotherapy
Extended treatment with zoledronate does not improve disease-free or overall survival in patients with high-risk early-stage breast cancer, according to the results of the SUCCESS A trial. Wolfgang Janni, MD, PhD, of the University Hospital Ulm, Germany, reported the results of this randomized, open-label trial in an oral session at the 2017 San Antonio Breast Cancer Symposium (SABCS; Abstract GS1-06).
Several recent studies reported benefits of adjuvant bisphosphonate treatment in patients with early-stage breast cancer, with improved survival and a reduced rate of recurrences in the bone, particularly in postmenopausal patients. The meta-analysis of these studies did not include comparative data on the duration of treatment in relationship to outcomes, which is why researchers initiated the SUCCESS A trial, examining 2 and 5 years of zoledronate treatment after adjuvant chemotherapy.
Nearly 3000 patients were available for analysis (1540 in the 5-year zoledronate group and 1447 patients in the 2-year zoledronate group). Disease-free survival and adapted overall survival rates did not differ between the two treatment durations, and further analysis of postmenopausal versus premenopausal women showed no difference in disease-free survival between the groups.